Good morning all,

QBIO is trading very well this morning on strong volume. Importantly, QBIO has hit a intra-day high of $1.98, right at the breakout level I talked about in my analysis. 

If it can breakout through this long term support / resistance level we could see a major move ahead.

Keep watching QBIO and look for opportunities as this important catalyst could be key.

All the best.


-------------------------------------------------------------------------------------------------


Subscribers,

Tuesday's brand new trade idea is Q BioMed, Inc (QBIO).

There are 3 key levels to watch on the chart below. 

The most important level is just below $2 which has been the long term support and resistance level as shown in green below. This is the key level going into tomorrow.

If QBIO can break through this level, we could see significant upside, just like it saw back in September last year and January this year.

As you can see in red, there has been a short term double bottom, and the blue line indicates an up-trending support.

All three lines are potentially bullish, and BarChart.com also rates QBIO as bullish.

About Q BioMed...

Q BioMed, Inc. is a biomedical acceleration and development company. They are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to meet their developmental potential so that they can provide products to patients in need.

QBIO aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. The Company's FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019.  Metastron is also approved for sale in 21 other countries. In addition to treating pain, Metastron has shown evidence of treating the cancer itself and extending survival. Q BioMed plans to conduct Phase IV trials to support label extension and cancer survival benefit using Metastron.

QBIO approaches biopharmaceutical development from a nontraditional angle. Rather than strictly devoting its resources to internal development, the company licenses what it deems to be undervalued biomedical assets in order to accelerate the achievement of clinical and commercial milestones. The company has five assets in its pipeline, led by its cancer palliation program, and diversified across multiple areas of significant medical need, including developmental nonverbal disorder, liver cancer and glaucoma.

Q BioMed Unlocks Undiscovered Biomedical Value

• Targets assets entering validation, clinical stages or commercialization leading up to value creating inflection points
• Deploys performance-based capital and resources to accelerate the development of an asset milestone achievement by its management
• Licenses or acquires the assets and works together to create valuation growth

How Q BioMed Accelerates Biomedical Technology Development

• Unlocks capital in US public markets to fund the development of assets
• Makes liquid investments in high-value assets that can produce exponential returns
• Diversifies risk over several therapies in various stages of development and deploys performance-based capital only
• Accelerates its asset’s development with management and advisory teams' expertise, experience, and industry relationships

You can visit their website at https://qbiomed.com for more information on the Company
 

QBIO has several bullish catalysts working in its favor...

• QBIO's strong corporate leadership led by CEO Denis Coran.

• A growing pipeline and strategy that mitigates risk & drives shareholder value.

• Acquired the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare.The agreement gives QBIO ownership of the brand, trademarks and market authorizations in 22 countries. In addition, all historical and current sales and distribution data related to those market authorisations will be assigned or transferred to QBIO to allow for as seamless a transition as possible in all markets.

• QBIO anticipates Metastron™ to start generating revenue in 1H 2019, with gross palliation revenue expected to be $20M-$40m p/a in year 3.

• QBIO's QBM-001 treatment for pediatric non-verbal disorder has $5B in global market potential.

• QBIO believes that it will complete formulation and manufacturing of QBM-001 by the end of the second quarter of 2019, after which it will file an investigational new drug (IND) application with the FDA. The company is hopeful that QBM-001 may receive the relevant designations from the FDA that could accelerate the development timeline. Assuming authorization from the FDA for the IND, the company believes it could begin a pivotal clinical trial of QBM-001 in the third quarter of 2019, which could lead to reviewed interim data as early as the first quarter of 2020.

• Technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada. The collaboration is focused on ophthalmic drug delivery and formulation experiments for MAN-01, a first-in-class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery.

Now what has us really excited about QBIO, is what we heard during CEO Denis Coran's audio interview with SmallCapVoice.com on January 15th.

At around the twelve minute mark, Mr. Coran hints at an upcoming FDA approval forQBIO's south Texas manufacturing facility.

Once approved QBIO can start producing Metastron™ commercially for sale in the U.S. and then internationally!

This drug is a substantial opportunity for QBIO. A very similar drug with a very narrow indication currently does almost $800 million a year in revenue!

This would be huge news, and could have a major impact on QBIO's stock price.

This is a great and informative interview, and it should get you excited about the incredible opportunity that QBIO presents you at the moment.

Recent Developments...

QBIO has announced some major developments in recent weeks and months, you can read the latest below or head to https://finance.yahoo.com/quote/QBIO to read them all and in full.

Q Biomed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression From Washington University

Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce it has exercised its option to exclusively license GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) from the Washington University in St. Louis. Determining the severity of glaucoma using this biomarker will aid in treatment decisions for patients diagnosed with, and being treated for, glaucoma. Currently, no single examination or diagnostic test is able to accurately predict disease progression.

Q BioMed's Autism Spectrum Disorder Drug Development Program Featured in February Issue of Leading Pharma/Biotech Newspaper

Q BioMed Inc. (QBIO), a biotechnology acceleration company, today announced that in the February issue of DDNews, journalists conducted an interview with Q BioMed CEO Dennis Corin, focused on the mechanism of action, development path, and market opportunities of QBM-001 which is being developed to help treat rare pediatric non-verbal autism spectrum disorder. DDNews is a respected monthly newspaper dedicated to the news of technology and business in the pharmaceutical and biotechnology industries.

Interviews with CEO Denis Corin of Q BioMed and CEO George Nikopoulos of Mannin Research

NEW YORK, Feb. 22, 2019 -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announces multiple interviews with the company’s CEO, Denis Corin, and the Q.

Demand for New Glaucoma Therapies Has Greatest Potential to Drive Value for Q BioMed's Shareholders

NEW YORK, NY / ACCESSWIRE / February 8, 2019 / Q BioMed (QBIO) has announced that it is bringing innovation to the treatment of Glaucoma- the the leading cause of irreversible blindness globally. The illness often remains undetected long after significant vision loss has already occurred and in the most common form, known as open-angle glaucoma, there are usually no symptoms and no pain associated with the increase in intraocular pressure that leads to optic nerve damage. A 2014 study published in Ophthalmology, the journal of the American Academy of Ophthalmology, by Y.C. Tham et al. of the Singapore Eye Research Institute projected that the number of people worldwide, aged 40 to 80 years, with glaucoma would grow from an estimated 64 million in 2013 to 76 million in 2020 and nearly 112 million people by the year 2040.

In Conclusion...

We think QBIO has some excellent catalysts for the short and long term future.

The chart appears bullish, and liquidity is excellent.

We urge members to do their research and be ready for the trading day ahead.


All the best.

SmallCapMomo.com

admin@smallcapmomo.com

Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity.